Evidence map›Paper›PMID 21801777›Full record

ArticleVaccine2011

Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: association with mucoadhesion and efficient penetration of the sublingual barrier.

William Domm, Lauren Brooks, Hung Li Chung, Changyong Feng, William J Bowers, Gene Watson, James L McGrath, Stephen Dewhurst

Abstract read
In one paragraph

Article in Vaccine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Buccal and sublingual vaccine delivery.Journal of controlled release : official journal of the Controlled Release Society · 2014
    Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

William DommDepartment of Microbiology and Immunology, University of Rochester, Rochester, NY 14627, USA.
Lauren Brooks
Hung Li Chung
Changyong Feng
William J Bowers
Gene Watson
James L McGrath
Stephen Dewhurst
University of Rochester · USEastman Chemical Company (United States) · US

Funding

Virology/Immunology CoreP30AI078498 · NIAID · UNIVERSITY OF ROCHESTER · PI DEWHURST, STEPHEN · 2008 to 2018
$14.6M
Transmission-blocking vaccine for HIV-1R01AI084111 · NIAID · UNIVERSITY OF ROCHESTER · PI DEWHURST, STEPHEN, ROSE, ROBERT C · 2009 to 2010
$1.1M
Use of Discontinuous Peptide Display for Generation of HIV Antigen MimicsR21AI087149 · NIAID · UNIVERSITY OF ROCHESTER · PI DEWHURST, STEPHEN · 2010 to 2011
$420k
NIAID NIH HHS P30 AI078498NIAID NIH HHS R01 AI084111NIAID NIH HHS R01AI084111NIAID NIH HHS R21 AI087149NIAID NIH HHS R21AI087149
6 · The paper itself

Abstract

The efficient induction of virus-specific mucosal antibodies is an important unmet objective in Human Immunodeficiency Virus Type-1 (HIV-1) vaccine research. One promising approach is sublingual (SL) immunization. We examined the effectiveness of SL delivery of two different viral vectors: (i) a recombinant adenovirus (rAd5), and (ii) a Herpes Simplex Virus Type-1 amplicon vector (HSV-1). Initial in vitro videomicroscopy experiments showed that rAd5 particles were trapped in saliva (i.e., that Ad5 was mucoadhesive) - unlike HSV-1 virions, which migrated freely in both saliva and water. In vivo imaging studies in mice revealed that only the rAd5 vector efficiently transduced the SL epithelium. Consistent with this, SL delivery of an rAd5 encoding HIV-1 envelope glycoprotein (Env) resulted in robust antigen-specific antibody responses in plasma and in vaginal washes, whereas SL delivery of a HSV-1 amplicon vector encoding HIV-1 Env failed to elicit Env-specific antibodies. In contrast, both vectors elicited equivalent humoral responses following intramuscular (IM) delivery. Finally, SL delivery of the rAd5:Env vector resulted in elevated levels of Env-specific serum IgA, and vaginal IgA and IgG, when compared to IM delivery of the same vector. These results findings shed light on vector properties (mucoadhesion, penetration of the sublingual barrier) which may be important for the induction of potent humoral immune responses following sublingual vector administration. Our data also show that SL delivery of an Env-encoding rAd5 vector can elicit a potent antigen-specific mucosal antibody response in the absence of adjuvant. Overall, these findings support the further exploration of the SL delivery route for HIV-1 vaccine delivery.

Indexed as

AdenoviridaeAdministration, SublingualAIDS VaccinesAnimalsAntibodies, NeutralizingCell Lineenv Gene Products, Human Immunodeficiency VirusFemaleGenetic VectorsHEK293 CellsHerpesvirus 1, HumanHIV-1HIV AntibodiesHumansImmunity, HumoralImmunity, MucosalAIDS VaccinesAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesImmunoglobulin AImmunoglobulin G

Identifiers

PMID21801777
PMCPMC3167942
OpenAlexW2038926101

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.